Truveta is a United States-based company that specializes in aggregating and analyzing de-identified electronic health record data from a network of health systems. Its platform supports the generation of real-world evidence for use in clinical research, drug development, and healthcare decision-making across multiple therapeutic areas including metabolic diseases, cardiology, and oncology.
The company provides retrospective data analysis capabilities that enable studies on treatment outcomes, patient populations, and disease management in everyday clinical settings. Its database has been referenced in research examining medications such as Wegovy for conditions like MASH, supplying the electronic medical record information needed for such analyses.
Truveta operates exclusively within the United States and maintains partnerships with various health providers to expand its data resources while adhering to privacy and regulatory standards. As a privately held entity, it focuses on delivering compliant data solutions that complement traditional clinical trials and inform regulatory and industry insights.
In the healthcare data industry, Truveta positions itself as a provider of large-scale, real-world datasets that help life sciences organizations and researchers access diverse patient information for evidence generation and population health studies.
None yet. When a new project in the record names Truveta as owner, partner or investor, it shows here.
Real‑world cohorts showed Wegovy 2.4 mg was associated with larger reductions in body weight, AST/ALT, and HbA1c versus resmetirom or no semaglutide in adults with MASH.
